
Becton, Dickinson and Company Investor Relations Material
Latest events

M&A Announcement
Becton, Dickinson and Company
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Becton, Dickinson and Company
Access all reports
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's principal businesses are based upon its expertise in the areas of vascular access devices (VADs), hemostasis systems and technologies, bioscience research tools for cell culture reagents and assays, transfusion technologies through a majority ownership interest in C.R. Bard Incorporated; Point-of-care testing instruments covering blood collection with red cell alloimmunization detection capability; transcutaneous immunoglobulin (Ig) replacement therapy; nutritionals.
Key slides for Becton, Dickinson and Company


Q2 2025
Becton, Dickinson and Company


Q1 2025
Becton, Dickinson and Company
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
BDX
Country
🇺🇸 United States